Clinicopathological Predictors of Sustained Viral Response Rates in Patients with Chronic Hepatitis C Infection

Nachnani, Jagdish; Gidwani, Raja; Sadeddin, Esmat; Clarkston, Wendell K.; Fiorella, Rusell; Alba, Laura

doi:10.14309/00000434-200709002-00354

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All guidelines recommend to perform a quantitative assessment of HCV RNA at week 12 of treatment. EVR is highly predictive of SVR and provides a valuable tool to decide on continuation and duration of treatment, as well as providing patients with an additional motivation to adhere to treatment [37][38][39]. In this study, majority of the patients had attained EVR (240 out of 250; 96.0%).…”

Section: Discussionmentioning

confidence: 60%

Impact of IL28B genetic variant's and viral genotype on treatment outcome of hepatitis C infected patients

Khan

Shoukat

Mudassar

et al. 2018

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Viral genotype and variation in host genes involved in the immune response may predict the treatment response in patients infected with HCV. The present study was designed to determine the distribution pattern of HCV and host genotypes in Chronic Hepatitis C (CHC) patients and their association with virological response and other risk factors. Methodology: Two hundred and fifty (n = 250) HCV positive patients were included in the study. HCV and Interleukin 28B (IL28B) genotyping was carried out by PCR-RFLP. Results: Viral genotype 3 was the predominant genotype seen in 187 (74.8%) patients. Wild genotype predominated in rs12979860, rs12980275 and rs8099917 SNP of IL28B gene. A significant difference was found in end stage virological response (EVR) between HCV genotype 1 infected patients with wild and variant genotype for rs12980275 and rs8099917 SNPs respectively (P < 0.05). On multivariate analysis all the SNPs were found to be associated with each other (P < 0.05) with rs12980275 SNP associated with history of Jaundice (P < 0.05). Viral genotype 3 was significantly associated with age (< 50 years) and rapid virological response (RVR) while as viral genotype 1 was significantly associated with history of surgery on multivariate analysis (P < 0.05). Conclusions: The viral genotype and IL28B polymorphisms are important factors to personalize antiviral therapy of patients with CHC.

show abstract

Section: Discussionmentioning

confidence: 60%

Impact of IL28B genetic variant's and viral genotype on treatment outcome of hepatitis C infected patients

Khan

Shoukat

Mudassar

et al. 2018

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…However, regarding sex of the patients, there was no significant difference between group I and II. On the contrary, Nachnani et al [23] mentioned that absence of early viral response; AST and ALT levels were independent predictors of absence of response to treatment in patients with chronic HCV infection receiving PEG-IFN and RBV combination treatment.…”

Section: Discussionmentioning

confidence: 95%

Assessment of Predictors for Early Resistance to Hepatitis C Virus Treatment

Mashad¹,

Tantawy²,

Elsayed³

et al. 2015

OJMM

View full text Add to dashboard Cite

The current standard of treatment for HCV is the combination of pegylated interferon (PEG-IFN) and ribavirin (RBV). Response to therapy is influenced by different factors related to virus or host characteristics. In this study we detected HCV genotype in some patients with chronic HCV infection-who received interferon plus ribavirin therapy and evaluating some risk factors in early resistance to treatment. These risk factors included age, gender, ALT& AST levels, HCV viral load & genotype. This study included 60 patients with chronic HCV infection and subjected to PEG-INF plus RBV therapy. 40 (gp I) had developed resistance after 12 weeks; while group II are the responders. on comparing patients in group I n = 40 (who developed resistance) to patients in group 2, no = 20 (responders), it has been found that the most important risk factors for developing resistance are the increased viral load of HCV-RNA, and AST.HCV-genotype as a risk factor was significantly higher among cases with genotype 1 and 4 and P value was 0.004. This was followed by ALT and AFP as risk factors with P value 0.004 for each and age with P value 0.026. However, regarding sex of the patients there was no significant difference between group I and II. In conclusion: the most frequent HCV genotype in resistant group were genotype I and IV, while in responder patient were genotype 2 & 3. The most important risk factor in this study is viral load and HCV genotype.

show abstract

“…Although ours is the first to predict LOE discontinuation in G1/4, numerous multivariable models attempting to predict nonresponse (independently of discontinuation behavior) have preceded ours. 10,12,14,16,17,36,58,59 The small scale and relative diversity of candidate predictors (some of which are rather obscure) identified in most of these models make them minimally useful in a clinical setting. Although viral genotype 60 and baseline viral load 10 are constituent data in the clinical management of HCV, clinicians have little reason to routinely test for other potential predictors such as viral genetic diversity, 14 gene expression, 59,61,62 or obscure laboratory or histological markers such as interferon-γ inducible protein 10 63 or anti-NS4a antibodies.…”

Section: Discussionmentioning

confidence: 99%

“…Observational studies of historical data have identified viral factors influencing LOE, such as baseline viral load, 10 viral kinetics in response to treatment, [11][12][13] and the virus's genetic diversity. 14 Patient, or host, factors that have been examined include general patient characteristics [14][15][16][17][18][19] and laboratory markers such as serum proteins. [20][21][22][23] Several studies have used US veteran databases to evaluate nonresponse and the likelihood of treatment discontinuation.…”

Section: Introductionmentioning

confidence: 99%

Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy

Nelson

Hoop²,

Korner³

et al. 2014

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Clinicopathological Predictors of Sustained Viral Response Rates in Patients with Chronic Hepatitis C Infection

Cited by 5 publications

References 0 publications

Impact of IL28B genetic variant's and viral genotype on treatment outcome of hepatitis C infected patients

Impact of IL28B genetic variant's and viral genotype on treatment outcome of hepatitis C infected patients

Assessment of Predictors for Early Resistance to Hepatitis C Virus Treatment

Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy

Contact Info

Product

Resources

About